US clearance for PharmaNetics' heparin test panel:
This article was originally published in Clinica
Executive Summary
PharmaNetics has received US FDA 510(k) clearance for its Heparin Management Panel and Accent system, which adds two new test cards, the Heparin Titration Test and the Protamine Response Test, as well as new hardware to the company's current Heparin Management Test, which runs on its Thrombolytic Assessment System (TAS). The Accent hardware automatically calculates information to manage anticoagulation in patients during cardiopulmonary bypass procedures. Bayer Diagnostics, which markets TAS as Rapidpoint Coag, will market the new product as Rapidpoint ACCENT. Raleigh, North Carolina-based PharmaNetics is the holding company of Cardiovascular Diagnostics.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.